Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (111-120 of 242) with videos related to

Pageof 25
Sort By:
Anticancer Research|February 11, 2014
Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancerFumihiko Hirai, Takashi Seto, Mototsugu Shimokawa, et al.
Clinical Lung Cancer|December 10, 2021
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)Naoki Haratake, Hidetoshi Hayashi, Mototsugu Shimokawa, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy of Taletrectinib (AB-106/DS-6051b) in <i>ROS1+</i> NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 StudiesSai-Hong Ignatius Ou, Yutaka Fujiwara, Alice T Shaw, et al.
Thoracic Cancer|July 25, 2019
Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patientsNaoki Haratake, Takashi Seto, Shinkichi Takamori, et al.
Cancer Science|February 7, 2019
Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumorsTaito Esaki, Fumihiko Hirai, Akitaka Makiyama, et al.
Investigational New Drugs|March 23, 2016
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumorsToshio Shimizu, Takashi Seto, Fumihiko Hirai, et al.
International Journal of Clinical Oncology|September 24, 2016
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancerNoboru Yamamoto, Koichi Goto, Makoto Nishio, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2008
Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinibHiroshi Wataya, Tatsuro Okamoto, Riichiroh Maruyama, et al.
Lung Cancer (Amsterdam, Netherlands)|August 6, 2013
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)Koichi Goto, Makoto Nishio, Noboru Yamamoto, et al.
Surgical Oncology|August 24, 2015
How should we manage small focal pure ground-glass opacity nodules on high-resolution computed tomography? A single institute experienceMasafumi Yamaguchi, Akio Furuya, Makoto Edagawa, et al.
Pageof 25

Showing results (111-120 of 242) with videos related to

Sort By:
Pageof 25
Anticancer Research|February 11, 2014
Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancerFumihiko Hirai, Takashi Seto, Mototsugu Shimokawa, et al.
Clinical Lung Cancer|December 10, 2021
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)Naoki Haratake, Hidetoshi Hayashi, Mototsugu Shimokawa, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy of Taletrectinib (AB-106/DS-6051b) in <i>ROS1+</i> NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 StudiesSai-Hong Ignatius Ou, Yutaka Fujiwara, Alice T Shaw, et al.
Thoracic Cancer|July 25, 2019
Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patientsNaoki Haratake, Takashi Seto, Shinkichi Takamori, et al.
Cancer Science|February 7, 2019
Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumorsTaito Esaki, Fumihiko Hirai, Akitaka Makiyama, et al.
Investigational New Drugs|March 23, 2016
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumorsToshio Shimizu, Takashi Seto, Fumihiko Hirai, et al.
International Journal of Clinical Oncology|September 24, 2016
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancerNoboru Yamamoto, Koichi Goto, Makoto Nishio, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2008
Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinibHiroshi Wataya, Tatsuro Okamoto, Riichiroh Maruyama, et al.
Lung Cancer (Amsterdam, Netherlands)|August 6, 2013
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)Koichi Goto, Makoto Nishio, Noboru Yamamoto, et al.
Surgical Oncology|August 24, 2015
How should we manage small focal pure ground-glass opacity nodules on high-resolution computed tomography? A single institute experienceMasafumi Yamaguchi, Akio Furuya, Makoto Edagawa, et al.
Pageof 25